Loading...
Loading...
- Shockwave Medical Inc's SWAV second-quarter FY21 sales were up 4-fold to $55.9 million beating the Wall Street consensus of $45.17 million.
- The growth was primarily driven by the launch of the coronary product, Shockwave C2, in the U.S. in February and the increased adoption of Shockwave products.
- Gross margin improved to 82% from 65% due to the launch of Shockwave C2 and continued improvements in manufacturing productivity and process efficiencies.
- Cash, cash equivalents, and short-term investments totaled $174.7 million.
- The company posted a Q1 EPS loss of ($0.01), much narrower than the loss of $(0.56) a year ago and surpassing the analyst consensus estimate of ($0.41) loss.
- Guidance: Shockwave Medical raised FY21 sales outlook of $218 million - 223 million (consensus of $200.64 million), higher than previous guidance of $195 million - $205 million.
- Price Action: SWAV shares are up 4.21% at $190.55 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in